Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) Return on Equity (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Return on Equity for 13 consecutive years, with 0.62% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity fell 5.0% year-over-year to 0.62%, compared with a TTM value of 0.62% through Dec 2025, down 5.0%, and an annual FY2025 reading of 0.52%, up 4.0% over the prior year.
  • Return on Equity was 0.62% for Q4 2025 at Fate Therapeutics, up from 0.65% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.2% in Q2 2021 and bottomed at 0.65% in Q3 2025.
  • Average Return on Equity over 5 years is 0.47%, with a median of 0.48% recorded in 2024.
  • The sharpest move saw Return on Equity grew 25bps in 2021, then crashed -32bps in 2022.
  • Year by year, Return on Equity stood at 0.31% in 2021, then plummeted by -97bps to 0.6% in 2022, then increased by 26bps to 0.45% in 2023, then dropped by -26bps to 0.57% in 2024, then decreased by -9bps to 0.62% in 2025.
  • Business Quant data shows Return on Equity for FATE at 0.62% in Q4 2025, 0.65% in Q3 2025, and 0.65% in Q2 2025.